Compare Mesoblast Limited (MESO) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Riot Platforms Inc — how do they compare? Mesoblast Limited trades at $14.32 (market cap $1.75B), while Riot Platforms Inc trades at $16.87 (market cap $6.32B). The key difference: Riot Platforms Inc is far larger — about 3.6× Mesoblast Limited's market cap, and Riot Platforms Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Riot Platforms Inc for 16 Days on average.
| MESO | RIOT | |
|---|---|---|
Market Cap | $1.75B | $6.32B |
Volume | 239,027 | 30,571,756 |
Sector | Health | Financials |
52-Week High | $20.96 | $28.67 |
52-Week Low | $13.19 | $11.83 |
Typical Hold Time | 14 Days | 16 Days |
Enterprise Value | $1.83B | $6.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
RIOT stock trades at $16.69, down 9.98% with bearish technical signals despite strong analyst support. The company shows concerning fundamentals with negative net income margins (-196.28%) and ROE (-48.24%), though revenue reached $647.44M in 2025. Recent strategic shift to data center services with $9.8B in contracted lease revenue through 2048 provides long-term visibility.
While analyst consensus remains strongly bullish (94.74% buy ratings) with $31.64 price target, execution risks persist given consecutive earnings misses and negative cash flow. The AI infrastructure pivot offers growth potential but requires careful monitoring of profitability improvements and Bitcoin market volatility exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
